QIAGEN reports preliminary Q3 2026 results
QIAGEN reported preliminary Q3 2026 net sales of $548 million at both reported and constant exchange rates, with adjusted diluted EPS of $0.65. Full Q3 results will be released November 4, 2026, but the company has suspended its full-year 2026 outlook and will not hold a conference call because of the pending EQT Private Equity transaction.
Key figures
- Eps
- 0.65
- Revenue
- 548000000
- Guidance
- Full-year 2026 outlook suspended while EQT transaction is pending
- Eps cer
- 0.65
- Revenue cer
- 548000000
AI analysis
Red flags2 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.